First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Plummer, R
Middleton, M
Wilson, R
Jones, C
Evans, J
Robson, L
Steinfeldt, H
Kaufman, R
Reich, S
Calvert, AH
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Churchill Hosp, Oncol Unit, Oxford OX3 7LJ, England
[3] Queens Univ Belfast, Dept Oncol, Belfast, Antrim, North Ireland
[4] Beatson Oncol Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland
[5] Canc Res UK, London, England
[6] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：208S / 208S
页数：1
相关论文
共 50 条
  • [41] Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.
    Perets, Ruth
    Geva, Ravit
    McKean, Meredith
    Goutopoulos, Andreas
    Erez, Omri
    Phadnis, Monica
    Youssoufian, Hagop
    Schwartz, Brian E.
    Kansra, Vikram
    Fattaey, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Bell, Maria
    Burkard, Mark E.
    Eickhoff, Jens C.
    Wilding, George
    LoConte, Noelle K.
    Traynor, Anne M.
    Hoang, Tien
    Heideman, Jennifer
    Kolesar, Jill
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
    Drew, Y.
    Ledermann, J. A.
    Jones, A.
    Hall, G.
    Jayson, G. C.
    Highley, M.
    Rea, D.
    Glasspool, R. M.
    Halford, S. E. R.
    Crosswell, G.
    Colebrook, S.
    Boddy, A. V.
    Curtin, N. J.
    Plummer, E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] A phase I trial of TRC102 (methoxyamine HCI) with temozolomide (TMZ) in patients with solid tumors and lymphomas.
    Meehan, Robert S.
    Coyne, Geraldine Helen O'Sullivan
    Kummar, Shivaani
    Collins, Jerry M.
    Anderson, Larry
    Zlott, Jennifer
    Juwara, Lamin
    Takebe, Naoko
    Piekarz, Richard
    Streicher, Howard
    Sharon, Elad
    Conley, Barbara A.
    Rubinstein, Larry
    Wilsker, Deborah
    Dull, Angie B.
    Ferry-Galow, Katherine V.
    Kinders, Roberti.
    Parchment, Ralph E.
    Doroshow, James H.
    Chen, Alice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.
    De Bono, Johann S.
    Tan, David Shao Peng
    Caldwell, Reece
    Terbuch, Angelika
    Goh, Boon C.
    Heong, Valerie
    Haris, Noor Md
    Bashir, Saira
    Hong, David S.
    Meric-Bernstam, Funda
    Bordia, Sonal
    Liu, Li
    Wilkinson, Gary
    Hreiki, Joseph
    Wengner, Antje
    Fischer, Kerstin
    Boix, Oliver
    Lagkadinou, Eleni
    Plummer, Elizabeth
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.
    Yap, Timothy A.
    Tolcher, Anthony W.
    Plummer, Elizabeth Ruth
    Becker, Andreas
    Fleuranceau-Morel, Patricia
    Goddemeier, Thomas
    Locatelli, Giuseppe
    Gounaris, Ioannis
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors.
    Chiappori, A
    Simon, GR
    Kvols, L
    Tetteh, L
    Mahany, JJ
    Lush, R
    Sullivan, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 160S - 160S
  • [48] Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors.
    Eads, Jennifer Rachel
    Krishnamurthi, Smitha S.
    Saltzman, Joel N.
    Bajor, David Lawrence
    Vinayak, Shaveta
    Barnholtz-Sloan, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.
    Westin, Shannon Neville
    Smart, Melody L.
    Pal, Navdeep
    Urbauer, Diana L.
    Janku, Filip
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Naing, Aung
    Tsimberidou, Apostolia Maria
    Fu, Siqing
    Falchook, Gerald Steven
    Hong, David S.
    Zinner, Ralph
    Subbiah, Vivek
    Culotta, Kirk Salvatore
    Lu, Karen H.
    Coleman, Robert L.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.
    El-Khoueiry, Anthony B.
    Desai, Jayesh
    Iyer, Swaminathan Padmanabhan
    Gadgeel, Shirish M.
    Ramalingam, Suresh S.
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345